Thplasma seeks $20 million financing as it expands plasma therapeutics platform

US Capital Global Securities is offering eligible investors a mix of equity and venture debt as Thplasma advances IVIG and albumin biosimilar development through an FDA-approved manufacturing partner.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.